Firethorn Wealth Partners LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,509 shares of the company’s stock after acquiring an additional 281 shares during the quarter. Johnson & Johnson accounts for 0.8% of Firethorn Wealth Partners LLC’s holdings, making the stock its 28th largest position. Firethorn Wealth Partners LLC’s holdings in Johnson & Johnson were worth $973,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. State Street Corp grew its holdings in Johnson & Johnson by 0.6% in the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Johnson & Johnson by 3.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after purchasing an additional 805,831 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares during the period. Finally, California Public Employees Retirement System grew its holdings in Johnson & Johnson by 2.7% in the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock valued at $1,919,726,000 after purchasing an additional 310,473 shares during the period. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
NYSE JNJ opened at $162.31 on Tuesday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.77 and a current ratio of 1.07. The firm has a market capitalization of $421.80 billion, a P/E ratio of 33.96, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. The stock’s fifty day moving average is $158.46 and its two-hundred day moving average is $166.96.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is presently 99.58%.
Wall Street Analysts Forecast Growth
JNJ has been the topic of several research analyst reports. StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Atlantic Securities lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Piper Sandler lowered their price target on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. SVB Leerink lowered their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Finally, Morgan Stanley lifted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $173.00.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are BuyingÂ
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
